Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.
HDAC
breast
cancer
clinicopathological
deacetylase
histone
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
08 Oct 2022
08 Oct 2022
Historique:
received:
06
06
2022
revised:
19
09
2022
accepted:
20
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
There is a strong association between malignancy and histone deacetylases (HDACs). Histone deacetylase inhibitors (HDACIs) are now being tested as antitumor agents in various clinical trials. We aimed to assess the clinical importance of HDAC-2 in breast cancer (BC). A total of 118 BC specimens were examined immunohistochemically. A statistical analysis was conducted in order to examine the relation between HDAC-2 and the clinicopathological features and survival of the patients. Higher HDAC-2 expression was related to lobular histological type of cancer, grade III, and stage III BC. In addition, the disease-free period and overall survival were curtailed and negatively related to the over-expression of HDAC-2. Other factors correlating with worse survival were histological types other than ductal or lobular, and the stage of the disease. This study showed a relationship between HDAC-2 and BC. Further studies are required in order to eventually potentiate the role of HDACIs as anticancer agents in BC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
There is a strong association between malignancy and histone deacetylases (HDACs). Histone deacetylase inhibitors (HDACIs) are now being tested as antitumor agents in various clinical trials. We aimed to assess the clinical importance of HDAC-2 in breast cancer (BC).
MATERIALS AND METHODS
METHODS
A total of 118 BC specimens were examined immunohistochemically. A statistical analysis was conducted in order to examine the relation between HDAC-2 and the clinicopathological features and survival of the patients.
RESULTS
RESULTS
Higher HDAC-2 expression was related to lobular histological type of cancer, grade III, and stage III BC. In addition, the disease-free period and overall survival were curtailed and negatively related to the over-expression of HDAC-2. Other factors correlating with worse survival were histological types other than ductal or lobular, and the stage of the disease.
CONCLUSIONS
CONCLUSIONS
This study showed a relationship between HDAC-2 and BC. Further studies are required in order to eventually potentiate the role of HDACIs as anticancer agents in BC.
Identifiants
pubmed: 36294811
pii: jpm12101672
doi: 10.3390/jpm12101672
pmc: PMC9604828
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27599530
Curr Opin Genet Dev. 1999 Apr;9(2):171-4
pubmed: 10322142
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Lancet Oncol. 2008 Feb;9(2):139-48
pubmed: 18207460
Mol Cancer Res. 2007 Oct;5(10):981-9
pubmed: 17951399
J Pers Med. 2021 Jul 10;11(7):
pubmed: 34357119
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Cancer. 2008 Dec 19;8:381
pubmed: 19099586
Lancet. 2005 May 14-20;365(9472):1727-41
pubmed: 15894099
Jpn J Clin Oncol. 2016 Oct;46(10):893-902
pubmed: 27432453
BMC Gastroenterol. 2015 Oct 26;15:148
pubmed: 26502922
Br J Cancer. 2011 Jun 7;104(12):1828-35
pubmed: 21559012
Am J Cancer Res. 2017 May 01;7(5):1213-1226
pubmed: 28560068
Anticancer Res. 2017 Jan;37(1):35-46
pubmed: 28011471
Cancer Res. 2001 Oct 1;61(19):7025-9
pubmed: 11585728
Cancer Nurs. 1994 Oct;17(5):418-28
pubmed: 7954390
Nature. 1997 Sep 25;389(6649):349-52
pubmed: 9311776
J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6
pubmed: 10922406
Ann Surg. 2005 Dec;242(6):791-800, discussion 800-1
pubmed: 16327489
Anticancer Res. 2018 Jan;38(1):37-43
pubmed: 29277754
Curr Med Chem. 2022;29(17):2979-2994
pubmed: 34525905
Mol Endocrinol. 2009 Mar;23(3):388-401
pubmed: 19106193
Tumour Biol. 2014 Jan;35(1):61-71
pubmed: 23873102
Oncogene. 2007 Aug 13;26(37):5420-32
pubmed: 17694083
J Adv Pract Oncol. 2015 Jan-Feb;6(1):22-36
pubmed: 26413372
Prostate. 2004 May 1;59(2):177-89
pubmed: 15042618
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8
pubmed: 11535817
Cell Death Dis. 2021 Aug 7;12(8):779
pubmed: 34365463
J BUON. 2018 Jul-Aug;23(4):846-861
pubmed: 30358185
Anticancer Res. 2018 Jul;38(7):3817-3824
pubmed: 29970501
Histopathology. 2008 Sep;53(3):267-77
pubmed: 18671804
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
pubmed: 10954755
Theranostics. 2020 Mar 4;10(10):4290-4307
pubmed: 32292495
Proc Natl Acad Sci U S A. 1964 May;51:786-94
pubmed: 14172992
BMC Cancer. 2013 Apr 30;13:215
pubmed: 23627572
J Pers Med. 2021 Mar 22;11(3):
pubmed: 33809844
Invest New Drugs. 2007 Feb;25(1):31-40
pubmed: 16865529
Anticancer Res. 2015 Jun;35(6):3129-35
pubmed: 26026072
Cell Stem Cell. 2007 Oct 11;1(4):353-5
pubmed: 18371369
Crit Rev Oncog. 2015;20(1-2):1-17
pubmed: 25746101
Anticancer Res. 2019 Mar;39(3):1119-1127
pubmed: 30842140
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
J Breast Cancer. 2014 Dec;17(4):323-31
pubmed: 25548579
J Cell Biochem. 2019 Jun;120(6):9172-9180
pubmed: 30618185
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):299-313
pubmed: 28870998
Expert Rev Hematol. 2015 Feb;8(1):9-18
pubmed: 25410127
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Cancer Res. 2008 Mar 1;68(5):1513-9
pubmed: 18316616
Nat Neurosci. 1999 Oct;2(10):867-72
pubmed: 10491605
Nat Rev Genet. 2009 Jan;10(1):32-42
pubmed: 19065135
Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):950-960
pubmed: 29509243
Anticancer Res. 2017 Oct;37(10):5355-5362
pubmed: 28982843
Genes Dis. 2018 May 12;5(2):77-106
pubmed: 30258937
J Cell Biochem. 2018 Feb;119(2):2168-2178
pubmed: 28857238
Expert Opin Investig Drugs. 2010 Sep;19(9):1049-66
pubmed: 20687783
Cancers (Basel). 2022 Jul 23;14(15):
pubmed: 35892859
J Am Dent Assoc. 2018 Apr;149(4):291-298
pubmed: 29439772
Int J Mol Med. 2021 Jul;48(1):
pubmed: 34013366
Cancer Res. 2006 Sep 1;66(17):8814-21
pubmed: 16951198
Mol Cell Probes. 2020 Oct;53:101649
pubmed: 32777446
Anticancer Res. 2016 Oct;36(10):5019-5024
pubmed: 27798860
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Curr Drug Targets. 2006 Nov;7(11):1553-60
pubmed: 17100594
Exp Cell Res. 2021 Sep 1;406(1):112722
pubmed: 34242623
BMC Cancer. 2014 Aug 20;14:604
pubmed: 25139823